Juniper Publishers-Cancer Therapy Oncology International Journal

  Cancer Therapy & Oncology - Juniper Publishers Abstract Protocol FOLFOX4 is a promising treatment option in advanced hepatocellular cancer patients as shown by Asian phase III trial - the EACH study. Given that most of the targeted therapies have not proven to be clinically significant or clinically relevant in the treatment advanced hepatocellular cancer, only sorafenib is at present an approved option the world over. Since sorafenib is not an affordable option, especially in developing countries where the burden is highest or for those who cannot be qualified for sorafenib in the western world, what are other options. After a thorough literature review it seems that if not Sorafenib, then probably we can treat patients with advanced hepatocellular cancer with chemotherapy protocol FOLFOX4. FOLFOX4 protocol has proved its safety and efficacy among advanced hepatocellular cancer patients in a phase III randomized trial - the EACH trial. EACH trial showed an

 Cancer Therapy & Oncology - Juniper Publishers Editorial Cancer is a group of disease characterized by the uncontrolled growth and spread of abnormal cells which may lead to death. According to a report by GLOBOCAN the number of new cancer cases would increase to 19.3 million by 2025 worldwide. Thus globally cancer has become a big threat to human beings, among various diseases. Carcinogen induced deregulation in cellular signaling pathway, may leads to the cancer development. Chemotherapy is an important mode of cancer treatment that used to cure and improve the patient’s quality of life [1]. At the same time chemotherapy is known to induce drug resistance and toxicity that hurdles the improvement of overall response and survival of cancer patients. Many cancers contain a sub-population of self-renewing and expanding stem cells known as cancer stem cells (CSCs). These are associated with chemotherapeutic resistant leading to tumor recurrence and poor patien